[go: up one dir, main page]

TR200103187T2 - Lipit matriks-ilaç konjugatlarından hazırlanan ilaç taşıyıcı. - Google Patents

Lipit matriks-ilaç konjugatlarından hazırlanan ilaç taşıyıcı.

Info

Publication number
TR200103187T2
TR200103187T2 TR2001/03187T TR200103187T TR200103187T2 TR 200103187 T2 TR200103187 T2 TR 200103187T2 TR 2001/03187 T TR2001/03187 T TR 2001/03187T TR 200103187 T TR200103187 T TR 200103187T TR 200103187 T2 TR200103187 T2 TR 200103187T2
Authority
TR
Turkey
Prior art keywords
drug
interaction
carrier prepared
lipid matrix
ldc
Prior art date
Application number
TR2001/03187T
Other languages
English (en)
Inventor
Helmut Müller Rainer
Olbrich Carsten
Original Assignee
Pharmasol Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19920908A external-priority patent/DE19920908A1/de
Priority claimed from DE19964085A external-priority patent/DE19964085A1/de
Application filed by Pharmasol Gmbh filed Critical Pharmasol Gmbh
Publication of TR200103187T2 publication Critical patent/TR200103187T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Bu bulus, partikül matriksi olarak saf bir lipit-ilaç konjügati (LDC) ve ya çesitli LDC' lerin karisimindan olusan, LDC içindeki bagin yapi olarak kovalen bag, eletrostatik etkilesim, dipol-dipol etkilesimi yayilim kuvvetleri, iyon etkilesimleri hidrojen baglari ve/veya hidrofobik etkilesim biçiminde oldugu, oda sicakliginda (20 C) kati çökelti halinde bulunan partiküllü aktif madde tasiyicilar ile ilgilidir.
TR2001/03187T 1999-05-07 2000-05-08 Lipit matriks-ilaç konjugatlarından hazırlanan ilaç taşıyıcı. TR200103187T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19920908A DE19920908A1 (de) 1999-05-07 1999-05-07 Arzneistoffträger zur kontrollierten Wirkstoffapplikation hergestellt aus Lipidmatrix-Arzneistoffkonjugaten (LAK-Partikel)
DE19964085A DE19964085A1 (de) 1999-12-27 1999-12-27 Arzneistoffträgr zur kontrollierten Wirkstoffapplikation hergestellt aus Lipidmatrix-Arzneistoffkonjugaten (LAK-Partikel)

Publications (1)

Publication Number Publication Date
TR200103187T2 true TR200103187T2 (tr) 2002-04-22

Family

ID=26053253

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/03187T TR200103187T2 (tr) 1999-05-07 2000-05-08 Lipit matriks-ilaç konjugatlarından hazırlanan ilaç taşıyıcı.

Country Status (11)

Country Link
US (1) US6770299B1 (tr)
EP (1) EP1176984B1 (tr)
JP (1) JP2002544177A (tr)
KR (1) KR20020012215A (tr)
AU (1) AU4563100A (tr)
BR (1) BR0010356A (tr)
CA (1) CA2372461A1 (tr)
DE (1) DE50013950D1 (tr)
MX (1) MXPA01011347A (tr)
TR (1) TR200103187T2 (tr)
WO (1) WO2000067800A2 (tr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200600877A1 (ru) * 2003-10-31 2006-12-29 Тева Фармасьютикал Индастриз, Лтд. Наночастицы для доставки лекарств
EP1698329A4 (en) * 2003-12-24 2009-10-28 Ltt Bio Pharma Co Ltd PHARMACEUTICAL NANOTEILS, METHOD FOR THE PRODUCTION THEREOF AND PARENTERALLY APPLIED PRODUCT FROM NANOTEILES
US7282194B2 (en) * 2004-10-05 2007-10-16 Gp Medical, Inc. Nanoparticles for protein drug delivery
US20070254037A1 (en) * 2004-12-15 2007-11-01 Youri Popowski Methods and Compositions for the Treatment of Cell Proliferation
EP1674081A1 (de) * 2004-12-23 2006-06-28 KTB Tumorforschungsgesellschaft mbH Herstellung von lipidbasierten Nanopartikeln unter Einsatz einer dualen asymmetrischen Zentrifuge
US9114077B2 (en) 2006-11-17 2015-08-25 Abbvie Deutschland Gmbh & Co Kg Nanocrystals for use in topical cosmetic formulations and method of production thereof
GB0623838D0 (en) * 2006-11-29 2007-01-10 Malvern Cosmeceutics Ltd Novel compositions
US20090053268A1 (en) * 2007-08-22 2009-02-26 Depablo Juan J Nanoparticle modified lubricants and waxes with enhanced properties
US20090061009A1 (en) * 2007-08-29 2009-03-05 Joseph Schwarz Composition and Method of Treatment of Bacterial Infections
WO2010063080A1 (en) * 2008-12-05 2010-06-10 Commonwealth Scientific And Industrial Research Organisation Amphiphile prodrugs
EP2229936B1 (en) * 2009-03-09 2015-05-06 PharmaSol GmbH Nanonized testosterone formulations for improved bioavailability
WO2012059936A1 (en) 2010-11-03 2012-05-10 Padma Venkitachalam Devarajan Pharmaceutical compositions for colloidal drug delivery
CN104127387A (zh) * 2014-02-21 2014-11-05 杭州长典医药科技有限公司 奥美拉唑钠特种超细粉体冻干制剂及其制备方法
BE1023491B1 (nl) * 2015-10-06 2017-04-06 Nutri-Ad International Nv Voedingsadditief voor gevogelte
JP7610208B2 (ja) * 2019-03-22 2025-01-08 インテグレイテッド ナノセラピューティクス インコーポレイテッド 足場部分から調製した脂質結合体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543390A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5554728A (en) * 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US5907030A (en) * 1995-01-25 1999-05-25 University Of Southern California Method and compositions for lipidization of hydrophilic molecules
DE19745950A1 (de) * 1997-10-17 1999-04-22 Dds Drug Delivery Service Ges Arzneistoffträgerpartikel für die gewebespezifische Arzneistoffapplikation

Also Published As

Publication number Publication date
KR20020012215A (ko) 2002-02-15
CA2372461A1 (en) 2000-11-16
DE50013950D1 (de) 2007-02-22
MXPA01011347A (es) 2004-06-03
BR0010356A (pt) 2002-02-13
EP1176984B1 (de) 2007-01-10
WO2000067800A3 (de) 2001-05-10
JP2002544177A (ja) 2002-12-24
US6770299B1 (en) 2004-08-03
WO2000067800A2 (de) 2000-11-16
AU4563100A (en) 2000-11-21
EP1176984A2 (de) 2002-02-06

Similar Documents

Publication Publication Date Title
TR200103187T2 (tr) Lipit matriks-ilaç konjugatlarından hazırlanan ilaç taşıyıcı.
ES2266041T3 (es) Proteina serica y celular de anclaje y conjugados.
Kolodych et al. Development and evaluation of β-galactosidase-sensitive antibody-drug conjugates
TR200101751T2 (tr) Poliol-IFN-beta konjugatları
EP0495265B1 (en) Acid-labile linker molecules
US5137877B1 (en) Bifunctional linking compounds conjugates and methods for their production
AU2012257418B2 (en) Bio-orthogonal drug activation
IL135148A0 (en) A polysaccharide conjugate and pharmaceutical compositions containing the same
Liu et al. Controlled loading of albumin-drug conjugates ex vivo for enhanced drug delivery and antitumor efficacy
JPH01500435A (ja) 先端的抗癌療法及びその実施のための細胞毒性薬物
CA2391534A1 (en) Selective cellular targeting: multifunctional delivery vehicles
DE50014571D1 (de) Träger-pharmaka-konjugate
TR199802289A2 (tr) Fosfonasit-ikame etmis benzazepinon-n-asetikasit türevleri.
WO2001036003A2 (en) Selective cellular targeting: multifunctional delivery vehicles
FI97692C (fi) Menetelmä terapeuttisesti käyttökelpoisen aktivaattori-kohdistusosa -konjugaatin ja esilääkkeen valmistamiseksi
Kratz et al. Preparation, characterization and in vitro efficacy of albumin conjugates of doxorubicin
ES2331303T9 (es) Conjugados polimericos sensibles al ph de un farmaco cancerostatico de antraciclina para terapia dirigida.
Wilchek Affinity therapy and polymer bound drugs
Nogusa et al. Structure–activity relationships of carboxymethylpullulan-peptide-doxorubicin conjugates—systematic modification of peptide spacers
DK1142905T3 (da) Hidtil ukendt depsipeptidforbindelse
EP0464135B1 (en) Composition for reducing side effects of a drug
Le Sann Maleimide spacers as versatile linkers in the synthesis of bioconjugates of anthracyclines
Suzawa et al. Synthesis and HPLC analysis of enzymatically cleavable linker consisting of poly (ethylene glycol) and dipeptide for the development of immunoconjugate
US20100227798A1 (en) Use of the staudinger ligation in in vivo assembly of a biologically active compound
Satchi PDEPT: Polymer directed enzyme prodrug therapy